Samples

Revenue segments as reported by the company.

Test revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Change in fair value of contingent consideration

Asset impairment

Restructuring

Gain on sale of RUO kit assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Invitae

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Invitae reports strong Q4 earnings, eyes growth amid challenges

Invitae's Q4 2022 performance showcased revenue growth, improved margins, and reduced cash burn, positioning the company for sustainable growth.
Strategic investments in key growth areas and a focus on customer experience and profitability underpin Invitae's vision for the future.
Addressing supply chain challenges while seizing opportunities for expansion and innovation will be critical for Invitae's continued success.

Invitae (NVTA) reports robust Q1 earnings and advances in PCM technology

Invitae's Q1 2023 earnings call highlighted strong financial performance, operational strengths, and strategic advancements in PCM technology.
The company's focus on growth, margin expansion, and debt management underscores a path towards sustainable profitability.
While facing challenges in reimbursement dynamics and competitive landscape, Invitae remains poised to capitalize on growth opportunities.

Invitae reports Q2 revenue growth, adjusts guidance amid challenges

Invitae shows progress towards profitability with improved margins and reduced cash burn.
Challenges in hereditary cancer revenue and PGX exit impact revenue guidance.
Focus on expanding customer base, improving reimbursement, and reducing cash burn.
Continuous investment in products for future growth and competitiveness.

Invitae reports robust Q3 earnings, addresses financial concerns proactively

Invitae's Q3 2023 performance was strong, with revenue growth and margin expansion. The company faces challenges in capital structure and insurance payments but is actively addressing them. Opportunities lie in revenue growth, operational improvements, and expanding genetic testing services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people.  Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today.  What’s our plan? It takes three steps:  --Make genetic testing more affordable and accessible than ever before. --Build a secure and trusted genome management infrastructure. --Design a new global community for sharing genetic information to advance science and medicine.  Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people.

Invitae's (NVTA) CEO Sean George on Q4 2021 Results - Earnings Call Transcript

SAN FRANCISCO, Feb. 24, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and year ended December 31, 2021. "2021 was another year of industry leading growth and the addition of almost 1 million patients onto the Invitae platform, providing further evidence that the Invitae vision and one-of-a-kind testing, digital health and data network are ushering in the era of genomic health management," said Sean George, Ph.D.

Invitae Reports $460.4 Million in Annual Revenue Driven by 1.17 Million in Billable Volume in 2021

Coinbase

EOG Resources

Etsy

Block

Will earnings matter for these 5 trending stocks?

This Week's 5 Must-See Earnings Charts

SAN FRANCISCO, Feb. 16, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of FusionPlex Dx® and LiquidPlex Dx™ in Europe, part of its industry-leading Anchored Multiplex PCR chemistry in-vitro diagnostic (IVD) products. Invitae is delivering essential high quality innovation for precision oncology in the fight against cancer.

Invitae Launches its First CE-IVD Cancer Testing Kits In Europe

SAN FRANCISCO, Feb. 10, 2022 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m.

Invitae to Announce Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022

Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Invitae (NVTA) Q4 Earnings Expected to Decline

Invitae (NVTA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why Invitae (NVTA) is Poised for a Turnaround After Losing 30.9% in 4 Weeks

Bilibili

Iovance Biotherapeutics

iQIYI

Peloton

TG Therapeutics

Tencent Music Entertainment Group 

Bargain-hunting investors have good reason to be tempted, but a steep sell-off alone isn't enough of a bullish argument.

Are These 7 of the Worst-Performing Stocks of 2021 Ready to Skyrocket This Year?

Invitae Corporation (NVTA) CEO Sean George on JPMorgan 40th Annual Healthcare Conference (Transcript)

SAN FRANCISCO , Jan. 10, 2022 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2021 revenue, billable volume and commercial metrics reporting approximately 64 percent growth in revenue and 76 percent growth in volume, signaling continued momentum into 2022. "We are encouraged by the acceleration of our business in 2021, particularly in light of the direct and indirect impacts on the healthcare system throughout the year," said Sean George, Ph.D.

Invitae Reports Preliminary 2021 Revenue of More Than $458 Million and Billable Volume of More Than 1.16 Million

SAN FRANCISCO, Jan. 5, 2022 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, chief executive officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 9:45 a.m.

Invitae to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Before buying shares, investors need to think about Invitae's most significant red flag.

Should You Invest in Invitae Right Now?

Biogen

Bristol-Myers

Cameco

Equity Commonwealth

MasTec

Muhlenkamp & Co. Inc., the investment firm founded by Ronald Muhlenkamp (Trades, Portfolio), released its portfolio for the third quarter earlier this month.

Muhlenkamp's Firm Buys Equity Commonwealth, Dumps 2 Stocks

Investors need to pay close attention to Invitae (NVTA) stock based on the movements in the options market lately.

Implied Volatility Surging for Invitae (NVTA) Stock Options

The big news from Invitae's Q3 update was a worsening bottom line.

What Especially Stood Out From Invitae's Q3 Results

Jumia

Zillow

Even at all-time high index levels, there are stocks to buy. The brutal earnings dips are an opportunity to scoop up the strong outlooks.

3 Stocks to Buy From Catastrophic Price Action

Exact Sciences

Quantum-Si

Shares of these genomics stocks have fallen far enough this year to attract some bargain shoppers.

3 Beaten-Down Genomics Stocks: Can They Recover?

Invitae Corp's (NYSE: NVTA) Q3 sales increased 66% Y/Y to $114.4 million, missing the consensus Wall Street estimate of $126.55 million. Invitae posted an 89% increase in billable test volume.

Why Are Invitae's Shares Plunging Today?

Hims & Hers Health

Novavax

Analyst price targets for three top growth stocks suggest big gains just up ahead.

3 Stocks That Could Soar 46% or More, According to Wall Street

Invitae Corporation (NVTA) CEO Sean George on Q3 2021 Results - Earning Call Transcript

Invitae (NVTA) delivered earnings and revenue surprises of -17.39% and -8.70%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Invitae (NVTA) Reports Q3 Loss, Lags Revenue Estimates

SAN FRANCISCO, Nov. 8, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2021. "Year-over-year growth continued at a fast pace in the third quarter as volumes remained strong across the platform," said Sean George, Ph.D.

Invitae Reports $114.4 Million in Revenue Driven by 296,000 in Billable Volume in Third Quarter of 2021

SAN FRANCISCO, Nov. 8, 2021 /PRNewswire/ -- Investigators from Northwestern University Feinberg School of Medicine and Invitae (NYSE: NVTA), a medical genetics company, will present the results of a collaborative study on genetic testing for heritable cardiomyopathies and arrhythmias at the American Heart Association (AHA) Scientific Sessions on Saturday, Nov. 13. The study found combined genetic testing for heritable cardiomyopathies and arrhythmias identified clinically relevant variants for one in five patients suspected of having one of these conditions.

Northwestern University and Invitae Present New Research Highlighting the Importance of Genetic Testing for Cardiovascular Conditions at the American Heart Association Scientific Sessions

Invitae (NYSE:NVTA) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement.

News for Invitae Stock (NVTA)